Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 003850Orphan Drug420 approvals134 trials

Boryung Corporation

Official website

Founded in 1963 and listed in 1988, Boryung is a pharmaceutical and CDMO firm built around its antihypertensive drug Kanarb.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Boryung was founded in 1963 and listed on the KOSPI in 1988 as a pharmaceutical and CDMO company. It manufactures its self-developed antihypertensive drug Kanarb along with products such as Gelfos (antacid), Mensoledam (analgesic), Duricef (antibiotic), and Astrix (antithrombotic), while developing new and improved drugs in hypertension, dyslipidemia, diabetes, CNS, oncology, and renal disease. The company operates two production sites, Ansan Campus and Yesan Campus, and two R&D centers in Seoul and Gwanggyo, Gyeonggi-do, recording consolidated revenue of about KRW 1,017.4 billion and operating profit of about KRW 65.1 billion in 2025.

Products & technology

  • GelfosAntacid
  • 구심
  • 용각산
  • CaprilAntihypertensive
  • MensoledamAnti-inflammatory analgesic
  • DuricefAntibiotic
  • AstrixAntithrombotic
  • KanarbAntihypertensive (single-agent ARB)

Regulatory approvals

data.go.kr

1 Orphan Drug designations · 2023 / 381 Korean MFDS drug approvals · 1966–2026 / 38 Korean MFDS device approvals · 1998–2018

  • OrphanBR1018012023-07-18
    Orphan Drug designation · in development20230119023
  • MFDS drugVonob Tablet 10mg2026-08-24
    Drug · Prescription · Approval202602453
  • MFDS drugVonob Tablet 20mg2026-08-24
    Drug · Prescription · Approval202602454
  • MFDS drugTRUEMPA LM XR Tablet 25/5/1000mg2026-06-18
    Drug · Prescription · Approval202601730
  • MFDS drugTRUEMPA LM XR Tablet 10/5/1000mg2026-06-18
    Drug · Prescription · Approval202601731
  • MFDS drugBRedox tab. 15mg2026-05-28
    Drug · Prescription · Approval202601537
  • MFDS drugBRedox tab. 30mg2026-05-28
    Drug · Prescription · Approval202601538
  • MFDS drugBRedox tab. 60mg2026-05-28
    Drug · Prescription · Approval202601539
  • MFDS drugGelfos Double Action Tab.2026-05-28
    Drug · OTC · Notification202601555
  • MFDS drugLzerozet Tablet 1/10mg2026-04-24
    Drug · Prescription · Approval202601206
  • MFDS drugEPO One Prefilled Injection2026-04-10
    Drug · Prescription · Approval202601025
  • MFDS drugEPO One Prefilled Injection2026-04-10
    Drug · Prescription · Approval202601026
Show 68 more
  • MFDS drugEPO One Prefilled Injection2026-04-10
    Drug · Prescription · Approval202601027
  • MFDS drugKanarbzet Tab. 60/20/10mg2026-02-27
    Drug · Prescription · Approval202600605
  • MFDS drugKanarbzet Tab. 60/10/10mg2026-02-27
    Drug · Prescription · Approval202600606
  • MFDS drugKanarbzet Tab. 30/20/10mg2026-02-27
    Drug · Prescription · Approval202600607
  • MFDS drugKanarbzet Tab. 30/10/10mg2026-02-27
    Drug · Prescription · Approval202600608
  • MFDS drugDasakin Tab. 100mg2026-02-27
    Drug · Prescription · Approval202600609
  • MFDS drugDasakin Tab. 80mg2026-02-27
    Drug · Prescription · Approval202600610
  • MFDS drugDasakin Tab. 70mg2026-02-27
    Drug · Prescription · Approval202600611
  • MFDS drugDasakin Tab. 50mg2026-02-27
    Drug · Prescription · Approval202600612
  • MFDS drugDasakin Tab. 20mg2026-02-27
    Drug · Prescription · Approval202600613
  • MFDS drugBRBCART Powder2025-10-10
    Drug · Prescription · Approval202502625
  • MFDS drugTRUEMPAL Tablet 10/5mg(Empagliflozin, Linagliptin)2025-09-10
    Drug · Prescription · Approval202502393
  • MFDS drugTRUEMPAL Tab. 25/5mg(Empagliflozin, Linagliptin)2025-09-09
    Drug · Prescription · Approval202502389
  • MFDS drugEasysant tab. 10/2.5mg2025-06-17
    Drug · Prescription · Approval202501483
  • MFDS drugTRUEMPA M XR Tablet 10/1000mg(Empagliflozin,Metformin)2025-05-29
    Drug · Prescription · Approval202501339
  • MFDS drugTRUEMPA M XR Tablet 25/1000mg(Empagliflozin,Metformin)2025-05-20
    Drug · Prescription · Approval202501234
  • MFDS drugAlimta Solution inj 25mg/mL2025-04-29
    Drug · Prescription · Approval202501037
  • MFDS drugTrudapa Tab. 5mg(Dapagliflozin Bis L-proline)2025-03-31
    Drug · Prescription · Approval202500734
  • MFDS drugTRUDS M XR Tab. 5/50/1000 mg2025-03-27
    Drug · Prescription · Approval202500712
  • MFDS drugLenvanib cap 4mg2025-02-06
    Drug · Prescription · Approval202500247
  • MFDS drugLenvanib cap 10mg2025-02-06
    Drug · Prescription · Approval202500248
  • MFDS drugLenvanib Cap 12mg2025-02-06
    Drug · Prescription · Approval202500249
  • MFDS drugTRUDS M XR Tab. 10/100/1000 mg2025-01-08
    Drug · Prescription · Approval202500059
  • MFDS drugAlimta Inj. 100mg2024-11-22
    Drug · Prescription · Approval202402765
  • MFDS drugAlimta Inj. 500mg2024-11-22
    Drug · Prescription · Approval202402766
  • MFDS drugRegoranib Tablet 40mg(Regorafenib)2024-11-06
    Drug · Prescription · Approval202402626
  • MFDS drugLetrobo Tab. 2.5mg((Letrozole)2024-10-18
    Drug · Prescription · Approval202402459
  • MFDS drugRabetrix Capsule 100/5mg2024-10-18
    Drug · Prescription · Approval202402464
  • MFDS drugPOMALIKIN Capsule 3mg (Pomalidomide)2024-08-09
    Drug · Prescription · Approval202401934
  • MFDS drugPOMALIKIN Capsule 2mg (Pomalidomide)2024-08-09
    Drug · Prescription · Approval202401935
  • MFDS drugPOMALIKIN Capsule 1mg (Pomalidomide)2024-08-09
    Drug · Prescription · Approval202401936
  • MFDS drugPOMALIKIN Capsule 4mg (Pomalidomide)2024-08-09
    Drug · Prescription · Approval202401937
  • MFDS drugMenthom LoxoTop Plaster2024-05-07
    Drug · OTC · Notification202401099
  • MFDS drugTRUDAPAL tablet 10/5mg2024-04-22
    Drug · Prescription · Approval202400936
  • MFDS drugZyprexa Tab. 2.5mg(Olanzapine)2024-03-27
    Drug · Prescription · Approval202400667
  • MFDS drugZyprexa Tab. 5mg2024-03-27
    Drug · Prescription · Approval202400668
  • MFDS drugZyprexa Tab. 10mg(Olanzapine)2024-03-27
    Drug · Prescription · Approval202400669
  • MFDS drugL50 Tab. 10/5mg2024-03-26
    Drug · Prescription · Approval202400664
  • MFDS drugTRULina M XR Tab. 5/1000mg(Linagliptin, Metformin)2024-03-22
    Drug · Prescription · Approval202400618
  • MFDS drugTRULina M XR Tab. 2.5/1000mg(Linagliptin, Metformin)2024-03-22
    Drug · Prescription · Approval202400619
  • MFDS drugBoryung Nicergoline Tab. 30mg2024-02-21
    Drug · Prescription · Approval202400372
  • MFDS drugBreathon prefilled syringe injection(Sugammadex Sodium)2023-11-30
    Drug · Prescription · Approval202303260
  • MFDS drugNaseron pre-filled syringe Inj. 0.3mg(Ramosetron HCl)2023-09-27
    Drug · Prescription · Approval202302850
  • MFDS drugMonteduo Tablet2023-08-30
    Drug · Prescription · Approval202302552
  • MFDS drugTRUBUDDY tablet 10/15mg(Dapagliflozin,Pioglitazone)2023-08-29
    Drug · Prescription · Approval202302547
  • MFDS drugTRUBUDDY tablet 10/30mg(Dapagliflozin,Pioglitazone)2023-08-29
    Drug · Prescription · Approval202302548
  • MFDS drugCebkhan Plus Tab.2023-08-10
    Drug · Prescription · Approval202302409
  • MFDS drugLzerozet Tablet 4/10mg2023-05-25
    Drug · Prescription · Approval202301673
  • MFDS drugLzerozet Tablet 2/10mg2023-05-25
    Drug · Prescription · Approval202301674
  • MFDS drugAkarb tablet 60/40mg2023-02-28
    Drug · Prescription · Approval202300720
  • MFDS drugAkarb tablet 30/40mg2023-02-28
    Drug · Prescription · Approval202300721
  • MFDS drugGemzarliquid Injection(Gemcitabine Hydrochloride)2023-02-14
    Drug · Prescription · Approval202300554
  • MFDS drugTRUDS Tab. 10/100 mg2023-01-26
    Drug · Prescription · Approval202300342
  • MFDS drugTRUSita M XR Tab. 50/750 mg2023-01-02
    Drug · Prescription · Approval202300020
  • MFDS drugTRUSita M Tab. 50/850 mg2022-12-21
    Drug · Prescription · Approval202204591
  • MFDS drugTRUSita M Tab. 50/500 mg2022-12-21
    Drug · Prescription · Approval202204592
  • MFDS drugTRUSita M Tab. 50/1000mg2022-12-21
    Drug · Prescription · Approval202204593
  • MFDS drugNafastar Injection 50milligram2022-09-22
    Drug · Prescription · Approval202203629
  • MFDS drugNafastar Injection 10milligram2022-09-22
    Drug · Prescription · Approval202203630
  • MFDS drugZepzelca Injection2022-09-22
    Drug · Prescription · Approval202203642
  • MFDS drugFinjuve Spray (Finasteride)2022-09-06
    Drug · Prescription · Approval202203492
  • MFDS drugMenthom IbuCool Plaster2022-08-12
    Drug · OTC · Notification202203274
  • MFDS drugLevlikin Capsule 20mg (Lenalidomide)2022-08-11
    Drug · Prescription · Approval202203255
  • MFDS drugInsevel tablet2022-07-18
    Drug · Prescription · Approval202203027
  • MFDS drugDukarb Plus Tab. 60/5/25mg2022-06-10
    Drug · Prescription · Approval202202455
  • MFDS drugTRUSita M XR 50/500mg2022-05-13
    Drug · Prescription · Approval202202021
  • MFDS drugTRUSita M XR 50/1000mg2022-05-13
    Drug · Prescription · Approval202202022
  • MFDS drugTRUSita M XR 100/1000mg2022-05-13
    Drug · Prescription · Approval202202023

Showing the 80 most recent of 420 records.

Clinical trials

data.go.kr

134 MFDS clinical trial authorisations · 2012–2026 (Phase 1 82 · Bioequivalence 32 · Phase 3 14 · Phase 2 5 · Phase 4 1)

  • Phase 1BR36002026-08-06

    2 trial sites

  • BioequivalenceBR74032026-05-20

    2 trial sites

  • BioequivalenceBR74032026-05-20

    2 trial sites

  • Phase 1BR30062026-05-15

    1 trial site

  • Phase 1BR30062026-05-15

    1 trial site

  • BioequivalenceBR74022026-04-24

    2 trial sites

  • Phase 1BR10182026-04-08

    1 trial site

  • Phase 1BR10182026-03-11

    1 trial site

  • Phase 1BR1015-A2026-02-10

    1 trial site

  • Phase 1BR1015-A2026-02-10

    1 trial site

  • Phase 1BR1015-A2026-01-12

    1 trial site

  • Phase 1BR1015-A2026-01-12

    1 trial site

Show 68 more
  • BioequivalenceBR54122025-12-18

    2 trial sites

  • BioequivalenceBR50022025-09-01

    1 trial site

  • Phase 2BR14002025-08-27

    31 trial sites

  • Phase 1BR74032025-07-28

    2 trial sites

  • Phase 1BR14022025-05-15

    1 trial site

  • Phase 1BR14022025-05-15

    1 trial site

  • Phase 1BR30062025-05-12

    1 trial site

  • Phase 1BR30062025-05-12

    1 trial site

  • Phase 2BR1018012025-05-07

    16 trial sites

  • BioequivalenceBR50022025-01-09

    2 trial sites

  • Phase 1BR74022024-12-09

    1 trial site

  • Phase 1BR10182024-11-29

    1 trial site

  • Phase 1BR1015-A2024-11-20

    1 trial site

  • Phase 1BR1015-A2024-11-20

    1 trial site

  • BioequivalenceBR54072024-11-20

    2 trial sites

  • Phase 1BR1015-A2024-11-19

    1 trial site

  • Phase 1BR1015-A2024-11-19

    1 trial site

  • BioequivalenceBR90112024-10-30

    2 trial sites

  • BioequivalenceBR20092024-10-22

    2 trial sites

  • Phase 1BR10172024-10-21

    1 trial site

  • Phase 1BR10172024-10-18

    1 trial site

  • BioequivalenceBR74012024-10-17

    2 trial sites

  • BioequivalenceBR74012024-10-17

    2 trial sites

  • Phase 2BR54022024-09-30

    25 trial sites

  • Phase 1BR50022024-09-02

    2 trial sites

  • BioequivalenceBR54002024-08-30

    2 trial sites

  • Phase 1BR14002024-08-27

    3 trial sites

  • Phase 1BR10192024-08-22

    1 trial site

  • Phase 1BR34092024-08-21

    1 trial site

  • Phase 1BR34092024-08-20

    1 trial site

  • BioequivalenceBR20092024-08-08

    2 trial sites

  • BioequivalenceBR50012024-07-08

    2 trial sites

  • BioequivalenceBR20212024-05-02

    4 trial sites

  • BioequivalenceBR20222024-03-11

    9 trial sites

  • Phase 1BR20162024-01-26

    2 trial sites

  • Phase 1BR30052023-12-28

    1 trial site

  • Phase 1BR30062023-12-28

    2 trial sites

  • Phase 1BR30062023-12-28

    2 trial sites

  • Phase 1BR30052023-12-28

    1 trial site

  • Phase 1BR10192023-11-24

    1 trial site

  • Phase 3BR10192023-10-30

    52 trial sites

  • Phase 1BR50012023-10-17

    1 trial site

  • Phase 1BR50022023-10-17

    1 trial site

  • Phase 1BR10172023-10-17

    1 trial site

  • BioequivalenceBR30072023-09-19

    1 trial site

  • Phase 3BR10182023-09-15

    28 trial sites

  • BioequivalenceBR20192023-07-18

    2 trial sites

  • BioequivalenceBR20192023-07-17

    2 trial sites

  • BioequivalenceBR20132023-06-28

    2 trial sites

  • Phase 1BR1015-A2023-06-27

    1 trial site

  • Phase 1BR1015-A2023-06-27

    1 trial site

  • Phase 1BR20162023-06-23

    2 trial sites

  • Phase 1BR20152023-06-22

    2 trial sites

  • Phase 1BR60022023-05-25

    2 trial sites

  • Phase 1BR60022023-05-24

    2 trial sites

  • Phase 3BR10172023-04-06

    26 trial sites

  • Phase 1BR30062023-04-04

    1 trial site

  • Phase 1BR30052023-03-15

    2 trial sites

  • Phase 1BR10192023-03-07

    1 trial site

  • Phase 1BR60012022-12-26

    1 trial site

  • Phase 1BR30042022-12-14

    1 trial site

  • Phase 1BR30042022-12-07

    1 trial site

  • Phase 3BR1015-A2022-08-02

    44 trial sites

  • Phase 1BR10182022-06-20

    1 trial site

  • BioequivalenceBR40042022-06-09

    2 trial sites

  • BioequivalenceBR40032022-06-09

    2 trial sites

  • BioequivalenceBR90122022-04-29

    2 trial sites

  • BioequivalenceBR90112022-04-14

    2 trial sites

Showing the 80 most recent of 134 records.

R&D and key agreements

Source: DART corporate disclosure

항암신약(First-in-class) · Oncology · Developing a first-in-class oncology drug candidate.

대사질환 신약 · 대사질환 · Developing a new drug for metabolic disease.

카나브 패밀리 임상연구 · 고혈압 등 만성질환(카나브 단일제·복합제) · Conducting various clinical studies for Kanarb single-agent and combination formulations.

Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

GC Medical Science Corporation7 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

SEWOONMEDICAL CO,. LTD.4 shared

Founded in 1982 and KOSDAQ-listed in 2008, Sewoon Medical manufactures medical aspirators and catheters/tubes.

OSANG HEALTHCARE CO.,LTD.2 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

ChoA Pharmaceutical Co., LTD.2 shared

Founded in 1996 and listed on KOSDAQ in 1999, ChoA Pharmaceutical is an OTC-focused drugmaker exporting to 23 countries worldwide.

Sugentech, Inc.2 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

DONG-A ST CO.,LTD2 shared

Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.

JW PHARMACEUTICAL2 shared

Founded in 1945, JW Pharmaceutical holds an original drug pipeline including Rivalo and Hemlibra, plus the IV nutrition product Winuf and OTC brand Hwakol.

SD BIOSENSOR INC.2 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

HUMASIS CO., LTD.1 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

SINSIN PHARMACEUTICAL Co., LTD.1 shared

Sinsin Pharmaceutical sells medicated patches and OTC medicines through direct deals with over 13,000 pharmacies nationwide.

Billions Co.,Ltd.1 shared

Founded in 1973, KOSDAQ-listed in 2001, Billions makes medical rubber products like condoms and runs an entertainment business.

YUHAN CORPORATION1 shared

Founded in 1926 and listed on the KOSPI in 1962, Yuhan Corporation is a comprehensive pharmaceutical company known for its innovative drug Leclaza.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition